VYGR Voyager Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VYGR

Price (delayed)

$7.88

Market cap

$427.89M

P/E Ratio

2.56

Dividend/share

N/A

EPS

$3.08

Enterprise value

$359.09M

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation ...

Highlights
Voyager Therapeutics's quick ratio has soared by 197% YoY and by 17% from the previous quarter
Voyager Therapeutics's net income has surged by 153% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.voyagertherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of VYGR
Market
Shares outstanding
54.3M
Market cap
$427.89M
Enterprise value
$359.09M
Valuations
Price to earnings (P/E)
2.56
Price to book (P/B)
1.47
Price to sales (P/S)
1.36
EV/EBIT
2.94
EV/EBITDA
2.84
EV/Sales
1.44
Earnings
Revenue
$250.01M
EBIT
$122.02M
EBITDA
$126.46M
Free cash flow
$74.66M
Per share
EPS
$3.08
Free cash flow per share
$1.74
Book value per share
$5.37
Revenue per share
$5.81
TBVPS
$8.17
Balance sheet
Total assets
$351.28M
Total liabilities
$114.96M
Debt
$0
Equity
$236.32M
Working capital
$255.18M
Liquidity
Debt to equity
0
Current ratio
4.96
Quick ratio
4.87
Net debt/EBITDA
-0.54
Margins
EBITDA margin
50.6%
Gross margin
100%
Net margin
52.9%
Operating margin
48.8%
Efficiency
Return on assets
40.8%
Return on equity
63.9%
Return on invested capital
106.2%
Return on capital employed
42.5%
Return on sales
48.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VYGR stock price

How has the Voyager Therapeutics stock price performed over time
Intraday
3.41%
1 week
4.1%
1 month
-15.36%
1 year
8.69%
YTD
-6.64%
QTD
-15.36%

Financial performance

How have Voyager Therapeutics's revenue and profit performed over time
Revenue
$250.01M
Gross profit
$250.01M
Operating income
$122.01M
Net income
$132.33M
Gross margin
100%
Net margin
52.9%
The operating income has surged by 181% since the previous quarter
Voyager Therapeutics's net income has surged by 153% QoQ
The company's net margin has surged by 147% YoY and by 60% QoQ
The operating margin has soared by 139% YoY and by 78% from the previous quarter

Growth

What is Voyager Therapeutics's growth rate over time

Valuation

What is Voyager Therapeutics stock price valuation
P/E
2.56
P/B
1.47
P/S
1.36
EV/EBIT
2.94
EV/EBITDA
2.84
EV/Sales
1.44
Voyager Therapeutics's EPS has soared by 132% from the previous quarter
VYGR's P/E is 41% below its last 4 quarters average of 4.2
VYGR's price to book (P/B) is 56% lower than its 5-year quarterly average of 3.2 and 25% lower than its last 4 quarters average of 1.9
VYGR's equity is up by 34% since the previous quarter
VYGR's price to sales (P/S) is 72% less than its 5-year quarterly average of 4.6 and 35% less than its last 4 quarters average of 2.0
The revenue has soared by 58% since the previous quarter

Efficiency

How efficient is Voyager Therapeutics business performance
VYGR's return on equity has surged by 195% year-on-year and by 99% since the previous quarter
Voyager Therapeutics's ROS has soared by 141% YoY and by 51% from the previous quarter
Voyager Therapeutics's return on assets has surged by 116% QoQ
Voyager Therapeutics's ROIC has soared by 102% YoY and by 19% from the previous quarter

Dividends

What is VYGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VYGR.

Financial health

How did Voyager Therapeutics financials performed over time
Voyager Therapeutics's quick ratio has soared by 197% YoY and by 17% from the previous quarter
VYGR's current ratio has surged by 188% year-on-year and by 17% since the previous quarter
The company's debt is 100% lower than its equity
VYGR's equity is up by 34% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.